MMP9 and ovarian carcinoma: Studies have shown that in ovarian cancer cells with high MMP-9 expression, the combined use of MMP9/MMP2 inhibitors and cisplatin could significantly enhance cytotoxicity, confirming that MMP9 is a potential therapeutic target for drug-resistant ovarian cancer [23].